The initiation of coverage by Barclays with an Equal-Weight rating suggests a neutral outlook for Alvotech. The price target of $10 provides a benchmark for investors, but does not necessarily indicate a strong upside or downside. Therefore, the short-term impact on the stock price is likely to be neutral.